AI Article Synopsis
- Sphingosine-1-phosphate (S1P) and its receptor (S1PR) play a significant role in immune-related inflammatory diseases, particularly inflammatory bowel disease like ulcerative colitis.* -
- Etrasimod is a new oral medication that selectively targets specific S1PRs, helping to prevent lymphocytes from moving into the bloodstream, which could lead to reduced inflammation.* -
- Clinical studies, including the phase II OASIS trial, have shown that etrasimod is effective and safe for patients with moderate to severe ulcerative colitis, making it a promising treatment option.*
Article Abstract
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2022-0255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!